Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

9.300 -0.320 (-3.33%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Arvinas: Q4 Earnings Insights
 
Via Benzinga
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces Chief Financial Officer Transition
From Arvinas Inc.
Via GlobeNewswire
Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease
From Arvinas Inc.
Via GlobeNewswire
Arvinas Inc. (NASDAQ: ARVN) Climbs to New 52-Week High
Via Investor Brand Network
Forecasting The Future: 6 Analyst Projections For Arvinas
 
Via Benzinga
Expert Outlook: Arvinas Through The Eyes Of 9 Analysts
 
Via Benzinga
Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
From CARRICK THERAPEUTICS LIMITED
Via GlobeNewswire
SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mixed, with the Nasdaq Composite gaining around 100 points on Friday. Shares of SPS Commerce, Inc. (NASDAQ: SPSC) rose sharply during Friday’s session following upbeat results. 
Via Benzinga
Topics Stocks
Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer
From Arvinas Inc.
Via GlobeNewswire
Analyst Ratings for Arvinas
 
Via Benzinga
Analyst Expectations for Arvinas's Future
 
Via Benzinga
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
From Arvinas Inc.
Via GlobeNewswire
Eaton Posts Strong Results, Joins Ferrari, Boot Barn And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. 
Via Benzinga
Topics Stocks
Arvinas Appoints Jared Freedberg as General Counsel
Awards Mr. Freedberg an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) 
From Arvinas Inc.
Via GlobeNewswire
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Comtech Telecommunications Corp. (NASDAQ: CMTL) moved lower during Friday’s session following weak quarterly earnings. 
Via Benzinga
Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday
U.S. stocks traded mostly higher, with the Dow Jones index gaining more than 40 points on Friday. 
Via Benzinga
Topics Stocks
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday. 
Via Benzinga
Topics Stocks
Arvinas, Pfizer Plan To Broaden Development Of Breast Cancer Candidate
Arvinas Inc (NASDAQ: ARVN) and Pfizer Inc (NYSE: PFE) released clinical data for vepdegestrant (ARV-471) in combination with  
Via Benzinga
Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program
From Arvinas Inc.
Via GlobeNewswire
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
From Arvinas Inc.
Via GlobeNewswire
Why Arvinas (ARVN) Shares Are Seeing Blue Skies
Arvinas Inc (NASDAQ: ARVN) shares are trading higher by 11.2% to $24.32 Monday morning after the company announced an oversubscribed $350 million private placement. 
Via Benzinga
Arvinas Announces Oversubscribed $350 Million Private Placement
From Arvinas Inc.
Via GlobeNewswire
Azenta Reports Upbeat Earnings, Joins Talis Biomedical, Sally Beauty And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded higher, with the Dow Jones gaining around 500 points on Tuesday. Shares of Azenta, Inc. (NASDAQ: AZTA) rose on Tuesday after the company reported better-than-expected fourth-quarter... 
Via Benzinga
Topics Stocks
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
Arvinas to Participate in Upcoming Investor Conferences
From Arvinas Inc.
Via GlobeNewswire
Matson To Rally Around 36%? Here Are 10 Top Analyst Forecasts For Tuesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.